Tvardi Therapeutics to host KOL webinar on TTI-109 potential in ulcerative colitis

PUBT · 1d ago
Tvardi Therapeutics to host KOL webinar on TTI-109 potential in ulcerative colitis
  • Tvardi Therapeutics will host a KOL webinar on Aug. 19, 2026 at 11:00 a.m. ET focused on TTI-109 in ulcerative colitis.
  • Session will feature new company data, a review of Phase 1 healthy-volunteer results, and a discussion of planned clinical development strategy.
  • Randy Longman, MD, PhD of Weill Cornell Medicine will join management to discuss the UC treatment landscape and unmet needs.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120800PRIMZONEFULLFEED9807093) on August 12, 2026, and is solely responsible for the information contained therein.